| Officer | Age | In this role | Source |
|---|---|---|---|
|
Ross Muken
Chief Executive Officer
Title from the Form 4 dated Nov 6, 2026
|
46 | Not stated | |
|
George Cardoza
Chief Financial Officer
|
64 |
Since 2024
2 years
|
|
|
Jurgi Camblong
Also a director
Executive Chairman
Title from the Form 4 dated Nov 10, 2026
|
47 | Not stated | |
|
Daan van Well
Chief Legal Officer
Title from the Form 4 dated Nov 9, 2026
|
51 | Not stated | |
|
Manuela da Silva Valente
Chief People Officer
|
56 |
Since 2019
7 years
|
|
|
Zhenyu Xu
Chief Scientific Officer
|
43 |
Since 2021
5 years
|
|
|
Philippe Menu
Chief Medical Officer and Chief Product Officer
|
44 | Not stated | |
|
Kevin Puylaert
Chief Sales Officer
Title from the Form 4 dated Oct 5, 2026
|
Not stated | Not stated | |
|
Abhimanyu Verma
Chief Technology Officer
Title from the Form 4 dated Oct 5, 2026
|
Not stated | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Related-party transactions come from the company’s proxy statement. SOPHiA GENETICS SA has not filed one with the SEC.
Loading...